Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giovanna Giuseppina Altobelli has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells

    by Jelena Dimitrov, Maurizio Maddalena, Cristina Terlizzi, Giovanna G. Altobelli, Sara Pellegrino, Tayyaba Mehmood, Viviana De Rosa, Francesca Iommelli, Silvana Del Vecchio

    Introduction: Neutrophil extracellular traps (NETs) are complex structures released by activated neutrophils that may modulate different steps of the metastatic cascade. The aim of our study was to investigate how NETs can modulate the adhesion properties of cancer cells and whether cell exposure to NETs can activate the epithelial-to-mesenchymal transition (EMT) program thus enhancing the migratory and invasive properties of tumor cells.Materials and methods: Different cancer cell lines were subjected to a solid-phase adhesion assay using NET-coated plates with or without the addition of antibodies against α5β1 or CCDC25 receptor. After 1-4 h of incubation, adherent cells were expressed as the percentage of total cell number. To test EMT occurrence, cells were treated with NETs for up to 48 h and then the levels of E-cadherin, vimentin, Snail, Slug, Zeb 1 and Twist 1 along with levels of Notch 1 and cleaved Notch 1 were determined by western blotting. Untreated and NET-treated cells were subjected to migration assays using 24-multiwell plates with transwell and FBS as chemoattractant.Results: Cancer cell adhesion to NET-coated plates varied between 30% and 92.7% and was significantly higher than that obtained in uncoated plates. The addition of antibodies against α5β1 or CCDC25 caused a strong reduction of cell adhesion to NETs. The prolonged exposure of EGFR-driven cancer cell lines to NETs caused the activation of the EMT program through the upregulation and cleavage of Notch 1 and was confirmed by the enhanced expression of EMT markers. The consequent loss of the epithelial phenotype induced a strong reduction of the expression of the oncogene driver. Cell migration was significantly enhanced in NET-treated cells as compared to untreated cells.Discussion: Our findings reveal the dynamic role of NETs that may provide a DNA and fibronectin rich environment for binding of many cancer cells at distant sites where the prolonged exposure to NETs triggers the EMT through the activation of Notch 1 signaling pathway with the subsequent enhancement of migratory and invasive properties of cancer cells. Furthermore, our findings provide an example of how an immune/inflammatory microenvironment may directly modulate the sensitivity of cancer cells to oncogene targeted agents.


  • Open Access

    ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors

    by Cristina Terlizzi, Viviana De Rosa, Francesca Iommelli, Antonio Pezone, Giovanna G. Altobelli, Maurizio Maddalena, Jelena Dimitrov, Caterina De Rosa, Carminia Maria Della Corte, Vittorio Enrico Avvedimento, et al.

    Background: ATM is a multifunctional serine/threonine kinase that in addition to its well-established role in DNA repair mechanisms is involved in a number of signaling pathways including regulation of oxidative stress response and metabolic diversion of glucose through the pentose phosphate pathway. Oncogene-driven tumorigenesis often implies the metabolic switch from oxidative phosphorylation to glycolysis which provides metabolic intermediates to sustain cell proliferation. The aim of our study is to elucidate the role of ATM in the regulation of glucose metabolism in oncogene-driven cancer cells and to test whether ATM may be a suitable target for anticancer therapy. Methods: Two oncogene-driven NSCLC cell lines, namely H1975 and H1993 cells, were treated with ATM inhibitor, KU55933, alone or in combination with oncogene driver inhibitors, WZ4002 or crizotinib. Key glycolytic enzymes, mitochondrial complex subunits (OXPHOS), cyclin D1, and apoptotic markers were analyzed by Western blotting. Drug-induced toxicity was assessed by MTS assay using stand-alone or combined treatment with KU55933 and driver inhibitors. Glucose consumption, pyruvate, citrate, and succinate levels were also analyzed in response to KU55933 treatment. Both cell lines were transfected with ATM-targeted siRNA or non-targeting siRNA and then exposed to treatment with driver inhibitors. Results: ATM inhibition deregulates and inhibits glucose metabolism by reducing HKII, p-PKM2Tyr105, p-PKM2Ser37, E1α subunit of pyruvate dehydrogenase complex, and all subunits of mitochondrial complexes except ATP synthase. Accordingly, glucose uptake and pyruvate concentrations were reduced in response to ATM inhibition, whereas citrate and succinate levels were increased in both cell lines indicating the supply of alternative metabolic substrates. Silencing of ATM resulted in similar changes in glycolytic cascade and OXPHOS levels. Furthermore, the driver inhibitors amplified the effects of ATM downregulation on glucose metabolism, and the combined treatment with ATM inhibitors enhanced the cytotoxic effect of driver inhibitors alone by increasing the apoptotic response. Conclusions: Inhibition of ATM reduced both glycolytic enzymes and OXPHOS levels in oncogene-driven cancer cells and enhanced apoptosis induced by driver inhibitors thus highlighting the possibility to use ATM and the driver inhibitors in combined regimens of anticancer therapy in vivo.


  • Open Access

    β3AR-dependent BDNF generation limits chronic post-ischemic heart failure

    by Seungho Jun, Alessandro Cannavo, Giuseppe Rengo, Federica Marzano, Jacopo Agrimi, Gizem Keceli, Andrea Elia, Daniela Liccardo, Giovanna G. Altobelli, Erhe Gao, et al.

    ID 24433 Poster Board 157 Rationale: Lack of brain-derived neurotrophic factor (BDNF) and/or inadequate expression/activity of its associated tropomyosin kinase receptor B (TrkB) account for brain and cardiac disorder. While β-adrenergic receptor (βAR) is responsible for the local expression of BDNF in neurons, whether a similar interaction is observed and pathophysiologically relevant in the cardiovascular system is unknown, especially in the post-ischemic myocardium with adrenergic desensitization. Moreover, it is unclear whether and how TrkB agonists counter chronic post-ischemic left ventricle (LV) decompensation. Methods: We conducted in vitro studies with neonatal rat (NRVM)/adult murine cardiomyocytes (CMs), SH-SY5Y neuronal cells, and umbilical vein endothelial cells. We assessed the degree of impact from ischemia-related injury via either in vivo coronary ligation (myocardial infarction, MI) or ex vivo isolated hearts with global ischemia-reperfusion injury (I/R) in WT, cardiomyocyte-selective BDNF KO (myoBDNF KO) or β3AR KO mice. Results: In WT hearts, early after MI (In vitro, the TrkB agonist, LM22A-4 promoted neurite outgrowth and neovascularization. Moreover, LM22A-4 and another agonist, TrkB, 7,8-dihydroflavone enhanced myocyte contractility. When given to in vivo MI mice, LM22A-4 rescued, at least in part, LV dysfunction, denervation, and hypovascularity. Of note, when given to isolated myoBDNF KO hearts, it no longer benefited post-I/R LV structure and function. Superfusing isolated murine myocyte with the β3AR-agonist, BRL-37344 enriched these cells with BDNF. Moreover, BRL-37344 limited post-I/R injury in WT mice but not in myoBDNF KO ones. Finally, the β1AR blocker that upregulates β3AR, augmented BDNF levels in the ischemic myocardium, improving in vivo post-MI dysfunction. Conclusions: Lack of BDNF accounts, at least in part, for chronic post-ischemic LV decompensation. By extension, by restoring intracardiac BDNF levels, TrkB agonists can limit the extent of ischemic injury, both in vivo and ex-in vivo. Direct and indirect cardiac β3AR stimulation via BRL-37344 or β-blocker, metoprolol, respectively, show another BDNF-centered means to arrest chronic post-ischemic HF. These findings may have relevant pharmacological implications for the treatment of chronic post-ischemic LV decompensation.

  • Open Access

    Use of Natural Agents and Agrifood Wastes for the Treatment of Skin Photoaging

    by Melania Parisi, Mariavittoria Verrillo, Maria Antonietta Luciano, Giuseppina Caiazzo, Maria Quaranta, Francesco Scognamiglio, Vincenzo Di Meo, Alessia Villani, Mariateresa Cantelli, Lucia Gallo, et al.

    Photoaging is the premature aging of the skin caused by repeated exposure to ultraviolet (UV) rays. The harmful effects of UV rays—from the sun or from artificial sources—alter normal skin structures and cause visible damage, especially in the most exposed areas. Fighting premature aging is one of the most important challenges of the medical landscape. Additionally, consumers are looking for care products that offer multiple benefits with reduced environmental and economic impact. The growing requests for bioactive compounds from aromatic plants for pharmaceutical and cosmetic applications have to find new sustainable methods to increase the effectiveness of new active formulations derived from eco-compatible technologies. The principle of sustainable practices and the circular economy favor the use of bioactive components derived from recycled biomass. The guidelines of the European Commission support the reuse of various types of organic biomass and organic waste, thus transforming waste management problems into economic opportunities. This review aims to elucidate the main mechanisms of photoaging and how these can be managed using natural renewable sources and specific bioactive derivatives, such as humic extracts from recycled organic biomass, as potential new actors in modern medicine.


  • Open Access

    Calcium/Calmodulin-Dependent Kinases in the Hypothalamus, Pituitary, and Pineal Gland: An Overview

    by Vincenzo Cimini, Susan Van Noorden, Cristina Terlizzi, Giovanna Giuseppina Altobelli

    We review the literature on the little-known roles of specific CaMKs in regulating endocrine functions of the pineal gland, the pituitary gland, and the hypothalamus. Melatonin activates hippocampal CaMKII, which then influences dendritogenesis. In the pituitary gland, the signal pathways activated by the CaMK in lower vertebrates, such as fishes, differ from those of mammals. In the teleost anterior pituitary, the activation of CaMKII induces the expression of somatolactin by glucagon b. In rats and humans, CaMKIVs have been associated with gonadotropes and thyrotropes and CaMKII with several types of human tumor cells and with a specific signaling pathway. Neuropeptides such as vasopressin and endothelin are also involved in the CaMKII signaling chain, as is the CaMKIIδ isoform which participates in generating the circadian rhythms of the suprachiasmatic nucleus. What arises from this review is that most of the hypothalamic CaMKs are involved in activities of the endocrine brain. Furthermore, among the CaMKs, type II occurs with the highest frequency followed by CaMKIV and CaMKI.


  • Open Access

    Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC

    by Viviana De Rosa, Francesca Iommelli, Cristina Terlizzi, Eleonora Leggiero, Rosa Camerlingo, Giovanna G. Altobelli, Rosa Fonti, Lucio Pastore, Silvana Del Vecchio

    Here, we tested whether co-targeting of glucose metabolism and oncogene drivers may enhance tumor response to tyrosine kinase inhibitors (TKIs) in NSCLC. To this end, pyruvate dehydrogenase kinase 1 (PDK1) was stably downregulated in oncogene-driven NSCLC cell lines exposed or not to TKIs. H1993 and H1975 cells were stably transfected with scrambled (shCTRL) or PDK1-targeted (shPDK1) shRNA and then treated with MET inhibitor crizotinib (1 µM), double mutant EGFRL858R/T790M inhibitor WZ4002 (1 µM) or vehicle for 48 h. The effects of PDK1 knockdown on glucose metabolism and apoptosis were evaluated in untreated and TKI-treated cells. PDK1 knockdown alone did not cause significant changes in glycolytic cascade, ATP production and glucose consumption, but it enhanced maximal respiration in shPDK1 cells when compared to controls. When combined with TKI treatment, PDK1 downregulation caused a strong enhancement of OXPHOS and a marked reduction in key glycolytic enzymes. Furthermore, increased levels of apoptotic markers were found in shPDK1 cells as compared to shCTRL cells after treatment with TKIs. Co-immunoprecipitation studies showed that PDK1 interacts with PKM2, Bcl-2 and Bcl-xL, forming macromolecular complexes at the ER–mitochondria interface. Our findings showed that downregulation of PDK1 is able to potentiate the effects of TKIs through the disruption of macromolecular complexes involving PKM2, Bcl-2 and Bcl-xL.


  • Calcium/calmodulin-dependent kinases can regulate the TSH expression in the rat pituitary

    by G. G. Altobelli, S. Van Noorden, D. Cimini, M. Illario, D. Sorriento, V. Cimini

    Purpose The endocrine secretion of TSH is a finely orchestrated process controlled by the thyrotropin-releasing hormone (TRH). Its homeostasis and signaling rely on many calcium-binding proteins belonging to the “EF-hand” protein family. The Ca2+/calmodulin (CaM) complex is associated with Ca2+/CaM-dependent kinases (Ca2+/CaMK). We have investigated Ca2+/CaMK expression and regulation in the rat pituitary. Methods The expression of CaMKII and CaMKIV in rat anterior pituitary cells was shown by immunohistochemistry. Cultured anterior pituitary cells were stimulated by TRH in the presence and absence of KN93, the pharmacological inhibitor of CaMKII and CaMKIV. Western blotting was then used to measure the expression of these kinases and of the cAMP response element-binding protein (CREB). TSH production was measured by RIA after time-dependent stimulation with TRH. Cells were infected with a lentiviral construct coding for CaMKIV followed by measurement of CREB phosphorylation and TSH. Results Our study shows that two CaM kinases, CaMKII and CaMKII, are expressed in rat pituitary cells and their phosphorylation in response to TRH occurs at different time points, with CaMKIV being activated earlier than CaMKII. TRH induces CREB phosphorylation through the activity of both CaMKII and CaMKIV. The activation of CREB increases TSH gene expression. CaMKIV induces CREB phosphorylation while its dominant negative and KN93 exert the opposite effects. Conclusion Our data indicate that the expression of Ca2+/CaMK in rat anterior pituitary are correlated to the role of CREB in the genetic regulation of TSH, and that TRH stimulation activates CaMKIV, which in turn phosphorylates CREB. This phosphorylation is linked to the production of thyrotropin.


  • Open Access

    Copper/Zinc Superoxide Dismutase in Human Skin: Current Knowledge

    by Giovanna G. Altobelli, Susan Van Noorden, Anna Balato, Vincenzo Cimini

    Superoxide dismutase is widespread in the human body, including skin and its appendages. Here, we focus on human skin copper/zinc superoxide dismutase, the enzyme that protects skin and its appendages against reactive oxygen species. Human skin copper/zinc superoxide dismutase resides in the cytoplasm of keratinocytes, where up to 90% of cellular reactive oxygen species is produced. Factors other than cell type, such as gender, age and diseased state influence its location in skin tissues. We review current knowledge of skin copper/zinc superoxide dismutase including recent studies in an attempt to contribute to solving the question of its remaining unexplained functions. The research described here may be applicable to pathologies associated with oxidative stress. However, recent studies on copper/zinc superoxide dismutase in yeast reveal that its predominant function may be in signaling pathways rather than in scavenging superoxide ions. If confirmed in the skin, novel approaches might be developed to unravel the enzyme's remaining mysteries.


  • Open Access

    Copper/Zinc-Superoxide Dismutase in Human Epidermis: An Immunochemical Study

    by Giovanna G. Altobelli, Susan Van Noorden, Vincenzo Cimini

    The localization of copper and zinc-superoxide dismutase in normal and neoplastic human skin was examined with immunochemical techniques. Skin samples were taken from males and females of different ages, UV exposed and non-exposed areas and basal-/spino-cellular carcinomas. The enzyme was localized diffusely in the cytoplasm and was also found in the nuclei of epidermal cells, endothelial cells and other dermis cell types. The dismutase content in the epidermis was higher in males than females, UV-exposed than non-exposed and young than old people. In the tumors, the enzyme content of the superficial epidermal layers was higher than in the deep tumoral epithelial cells. These data suggest that the localization of Cu, Zn-SOD in skin tissues reflects the gender and age of the subject, the cell types and their normal or diseased state. Further studies based on the investigation of systemic changes of this enzyme in physiological and pathological epidermis could provide additional information on tumor cell generation.


  • Analysis of calretinin early expression in the rat hippocampus after beta amyloid (1–42) peptide injection

    by Giovanna Giuseppina Altobelli, Donatella Cimini, Giuseppe Esposito, Teresa Iuvone, Vincenzo Cimini